Oxford Brain Health Clinical Trials Unit : All Pages
Oxford Brain Health Clinical Trials Unit
Copyright
Privacy Statement
Accessibility Statement
Oxford Mosaic Accessibility Statement
Oxford Mosaic Privacy Statement
About the Oxford Brain Health Clinical Trials Unit
Publications
Oxford Brain Health Clinical Trials Unit Staff
Collaborate
Research
News
Celebrating International Clinical Trials Day
Contact Us
Interventional and Diagnostic Research
Medical Technology and Devices
Developmental Studies
Patient and Public Involvement
Trial Management
Quality Assurance
The Maudsley bipolar disorder project Clinical characteristics of bipolar disorder I in a Catchment area treatment sample
The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder
The Maudsley Bipolar Disorder Project: The effect of medication, family history and duration of illness on IQ and memory in bipolar I disorder.
Prevalence of mental incapacity in medical inpatients and associated risk factors: cross-sectional study
The inter-rater reliability of mental capacity assessments
Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury
Focal brain damage protects against post-traumatic stress disorder in combat veterans
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)
Invitation to join the OBHCTU Patient and Public Involvement group
Job Opportunities at OBHCTU
Events and Training
Contact Us Form
OBHCTU Training Courses
Dr Vanessa Raymont
Nyla Haque
Fundamentals of Trial Management
Fundamentals of Quality Assurance
Natasha Sandle
Exploring the Issue of Diversity in Clinical Research, Special Edition
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia
Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s disease
The Validity of the Alcohol-Use-Disorder-Identification-Test and a Novel Proxy Test in the Assessment of Alcohol Consumption in the Cognitively Impaired Elderly
A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol
A phase II trial of tideglusib in Alzheimer's disease
Decision-making capacity for treatment in psychiatric and medical in-patients: cross-sectional, comparative study
Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography
Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans
Prof John Geddes
Jen Lawson
Jack Quaddy
Knowledge and Innovation Bulletin, September 2020
Knowledge and Innovation Bulletin, November 2020
Clinical Trials
Knowledge and Innovation Bulletin January 2021
Knowledge and Innovation Bulletin February 2021